Characteristics of Clinical Laboratory Indicators in Patients with Dengue Fever

Foshan Hospital of Traditional Chinese Medicine500 enrolled

Overview

The objective of this observational study was to understand the changes in laboratory indicators and clinical manifestations of dengue patients at various ages, and to provide new ideas for the treatment and prevention of dengue. The main questions it aims to answer are: 1 What are the key abnormal items in blood routine indicators of dengue patients? 2 Does dengue affect liver function in patients? Will there be liver damage? And when? 3. What are the specific clinical manifestations of dengue patients?

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Dengue Fever

Interventions

Observational studies did not involve any interventionsOTHER

Eligibility

Sex: ALL

Medical Language ↔ Plain English

* Inclusion Criteria\*\*: * Meet the clinical diagnostic criteria for dengue fever, with blood indicators showing that the dengue antigen is positive. * No age limit for inclusion. * Voluntarily agree to participate in the study and sign the informed consent. * Complete clinical data available, including symptoms and laboratory tests, to support subsequent analysis. * Exclusion Criteria\*\*: * Incomplete or unavailable clinical data. Patients will be excluded if sufficient laboratory data and symptoms cannot be collected. * Unable to understand or unwilling to sign the informed consent for any reason.

Locations (1)

Foshan Hospital of Traditional Chinese Medicine, Guangzhou University of Chinese Medicine, Foshan, 528051, Guangdong, China.

Foshan, Guangdong, China

Outcomes

Primary Outcomes

WBC

WBC (White Blood Cell count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

Time frame: From January 2024 to December 2024

HGB (Hemoglobin)

HGB (Hemoglobin), unit: g/dL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

Time frame: From January 2024 to December 2024

PLT (Platelet count)

PLT (Platelet count), unit: cells/µL; All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

Time frame: From January 2024 to December 2024

ANC (Absolute Neutrophil Count)

ANC (Absolute Neutrophil Count), unit: cells/µL. All these markers will be assessed at baseline (Day 0) and during monthly follow-up visits throughout the study period from January 2024 to December 2024. Data will be collected and summarized as.

Time frame: From January 2024 to December 2024

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.